Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
· ·
$3.89
▼ $0.07 (-1.8%)
Market data updated: 09/27 06:35 AM
News analyzed: 09/27/2026
Market Cap
$109.72M
Day Range
$3.84 - $4.11
52-Week Range
$3.82 - $18.79
Beta
—
Next Earnings
—
Support
$3.82
Resistance
$10.46
-70.2% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 1/11 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
MACD
MACD histogram is positive — rising momentum
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 17.1% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
CNXU’s overall investor score of 31, classified as 'WEAK,' reflects a pronounced technical weakness outweighing its mixed but more favorable news sentiment. The technical category, scoring only 18, highlights a clear downward bias: the stock trades below its 50-day moving average, exhibits a negative MACD histogram signaling declining momentum, and an RSI of 30.0—indicating oversold conditions—alongside a weak ADX (15.8) suggesting indecision. Meanwhile, the news category scores 56, driven by positive narratives around aesthetic medicine’s growth potential and broader healthcare sector momentum, though offset by a scheduled conference in late 2026 that could introduce short-term volatility. Risk, scoring 42, is primarily elevated by a high ATR (20.6% of price), signaling erratic price swings. The contrast between technical fragility and positive news underscores a stock where external factors may temporarily overshadow intrinsic weakness.
The stock shows consistent bearish signals: it trades below its 50-day moving average, has a negative MACD histogram, RSI of 30.0 (oversold), and an ADX of 15.8 (weak trend).
These indicators collectively suggest a short-term downtrend with limited upward momentum.
Positive news about aesthetic medicine’s growth opportunity and broader healthcare sector activity outweighs a single negative event (scheduled conference).
This could provide a counterbalance to technical weakness, but the timing of the conference may introduce uncertainty.
The ATR of 20.6% indicates high volatility relative to the stock’s price, increasing potential for sharp price swings.
This volatility could amplify losses or gains, depending on market conditions.
StockIQ conclusion
CNXU’s weak technical posture, characterized by a downward trend and high volatility, contrasts with positive news sentiment in its sector. While the stock may benefit from broader healthcare trends, its current technical indicators suggest caution. The high ATR and bearish signals indicate elevated risk, and any meaningful improvement would require a shift in momentum or external catalysts. Investors should monitor the scheduled conference and broader market conditions for potential turning points.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
35
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
Not enough data yet to generate this synthesis.
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
28
Risk
42
Sentiment
50
Fundamental
No data available
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Everyone's writing about Conexeu Sciences Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 3 vs. 3 out of the last 10 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
25
🎯 Conviction (vs. Emotion)
50
Psychology
96
Fundamentals
—
Technical
28
Valuation
—
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-65%
Market Narrative
33
Fundamental Reality
50
Narrative Gap
-17
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Morgan Housel — 0/100
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 97
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 80
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 61
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 51
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 31
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 25
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 88 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 3 positive, 4 neutral, 3 negative out of the last 10 articles.
CNW Group · 1.9.2026
Yahoo · 1.9.2026
GlobeNewswire · 1.9.2026
Yahoo · 1.9.2026
Benzinga · 31.8.2026
GlobeNewswire · 18.8.2026
GlobeNewswire · 11.8.2026
IPO-Edge.com · 3.8.2026
GlobeNewswire · 14.7.2026
GlobeNewswire · 7.7.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Conexeu Sciences Inc. (CNXU) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for CNXU specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
CNXU's technical score is 28/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 17.1% of price; Price is below the 50-day average; -70.3% over the last 3 months relative to the index.
StockIQ has no recorded dividend payment history for CNXU.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 4 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Sharpe Jeffrey Nathan | Exercise of Derivative Securities | 14.9.2026 | 500,000 | +500,000 | $0.00 |
| Sharpe Jeffrey Nathan | Exercise of Derivative Securities | 14.9.2026 | 500,000 | -500,000 | — |
| Sharpe Jeffrey Nathan | Exercise of Derivative Securities | 14.9.2026 | 500,000 | -500,000 | — |
| Sharpe Jeffrey Nathan | Exercise of Derivative Securities | 14.9.2026 | 1,500,000 | +500,000 | $0.00 |
| Purcell Lynn Sebastian | Option Exercise (in-the-money) | 4.9.2026 | 217,608 | +217,608 | $2.30 |
| Purcell Lynn Sebastian | Option Exercise (in-the-money) | 4.9.2026 | 217,608 | +217,608 | $0.00 |
| Purcell Lynn Sebastian | Option Exercise (in-the-money) | 4.9.2026 | 407,392 | +217,608 | $0.00 |
| Purcell Lynn Sebastian | Option Exercise (in-the-money) | 4.9.2026 | 2,951,848 | +217,608 | $2.30 |
| Purcell Lynn Sebastian | Option Exercise (in-the-money) | 4.9.2026 | 2,951,848 | +217,608 | $2.30 |
| Purcell Lynn Sebastian | Option Exercise (in-the-money) | 4.9.2026 | 407,392 | -217,608 | $0.00 |
| Purcell Lynn Sebastian | Open Market Purchase | 18.6.2026 | 202,500 | +202,500 | $0.00 |
| Purcell Lynn Sebastian | Exercise of Derivative Securities | 18.6.2026 | 202,500 | -202,500 | $0.80 |
| Wright Michael G. | Exercise of Derivative Securities | 18.6.2026 | 250,000 | +250,000 | $0.00 |
| Wright Michael G. | Exercise of Derivative Securities | 18.6.2026 | 250,000 | -250,000 | — |
| Purcell Lynn Sebastian | Open Market Purchase | 18.6.2026 | 202,500 | +202,500 | $0.80 |
| Wright Michael G. | Exercise of Derivative Securities | 18.6.2026 | 2,148,048 | +250,000 | $0.00 |
| Wright Michael G. | Exercise of Derivative Securities | 18.6.2026 | 250,000 | -250,000 | — |
| Purcell Lynn Sebastian | Open Market Purchase | 18.6.2026 | 2,734,240 | +202,500 | $0.80 |
| Purcell Lynn Sebastian | Open Market Purchase | 18.6.2026 | 625,000 | +202,500 | $0.00 |
| Purcell Lynn Sebastian | Exercise of Derivative Securities | 18.6.2026 | 625,000 | -202,500 | $0.80 |
| Wright Michael G. | Exercise of Derivative Securities | 26.5.2026 | 400,000 | -400,000 | — |
| Wright Michael G. | Exercise of Derivative Securities | 26.5.2026 | 400,000 | +400,000 | $0.00 |
| Wright Michael G. | Exercise of Derivative Securities | 26.5.2026 | 1,898,048 | +400,000 | $0.00 |
| Wright Michael G. | Exercise of Derivative Securities | 26.5.2026 | 500,000 | -400,000 | — |
| Sharpe Jeffrey Nathan | Exercise of Derivative Securities | 22.5.2026 | 500,000 | +500,000 | $0.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
172,079 shares short as of 2026-09-15 · vs. 202,485 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
54.6% of trading volume this week was short selling, vs. 57.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology